keyword
MENU ▼
Read by QxMD icon Read
search

Paul frankel

keyword
https://www.readbyqxmd.com/read/30168366/what-to-expect-that-you-re-not-expecting-a-pilot-video-education-intervention-to-improve-patient-self-efficacy-surrounding-discharge-medication-barriers
#1
Sanjai Sinha, John Dillon, Savira Kochhar Dargar, Alexi Archambault, Paul Martin, Brittney A Frankel, Jennifer Inhae Lee, Amanda S Carmel, Monika Safford
The objective of this study was to test the feasibility of video discharge education to improve self-efficacy in dealing with medication barriers around hospital discharge. We conducted a single-arm intervention feasibility trial to evaluate the use of video education in participants who were being discharged home from the hospital. The scores of pre- and post-intervention self-efficacy involving medication barriers were measured. We also assessed knowledge retention, patient and nursing feedback, follow-up barrier assessments, and hospital revisits...
August 31, 2018: Health Informatics Journal
https://www.readbyqxmd.com/read/30155518/sentinel-lymph-node-b-cells-can-predict-disease-free-survival-in-breast-cancer-patients
#2
Kim R M Blenman, Ting-Fang He, Paul H Frankel, Nora H Ruel, Erich J Schwartz, David N Krag, Lee K Tan, John H Yim, Joanne E Mortimer, Yuan Yuan, Peter P Lee
Tumor invasion into draining lymph nodes, especially sentinel lymph nodes (SLNs), is a key determinant of prognosis and treatment in breast cancer as part of the TNM staging system. Using multicolor histology and quantitative image analysis, we quantified immune cells within SLNs from a discovery cohort of 76 breast cancer patients. We found statistically more in situ CD3+ T cells in tumor negative vs. tumor positive nodes (mean of 8878 vs. 6704, respectively, p  = 0.006), but no statistical difference in CD20+ B cells or CD1a+ dendritic cells...
2018: NPJ Breast Cancer
https://www.readbyqxmd.com/read/30071968/-workin-on-our-night-moves-how-residents-prepare-for-shift-handoffs
#3
Laura G Militello, Nicholas A Rattray, Mindy E Flanagan, Zamal Franks, Shakaib Rehman, Howard S Gordon, Paul Barach, Richard M Frankel
BACKGROUND: Poor-quality handoffs have been associated with serious patient consequences. Researchers and educators have answered the call with efforts to increase system safety and resilience by supporting handoffs using increased communication standardization. The focus on strategies for formalizing the content and delivery of patient handoffs has considerable intuitive appeal; however, broader conceptual framing is required to both improve the process and develop and implement effective measures of handoff quality...
August 2018: Joint Commission Journal on Quality and Patient Safety
https://www.readbyqxmd.com/read/30071794/predictors-of-adverse-events-and-medical-errors-among-adult-inpatients-of-psychiatric-units-of-acute-care-general-hospitals
#4
Jentien M Vermeulen, Paul Doedens, Sara W Cullen, Mirjam J van Tricht, Richard Hermann, Martin Frankel, Lieuwe de Haan, Steven C Marcus
OBJECTIVE: The aim of this study was to identify factors associated with the occurrence of adverse events (AEs) or medical errors (MEs) during inpatient psychiatric hospitalizations. METHODS: A full-probability random sample of 4,371 charts from 14 inpatient psychiatric units at acute care general hospitals in Pennsylvania were reviewed in a two-stage process that comprised screening and flagging by nurses followed by review by psychiatrists. AE and ME rates were calculated overall and then stratified by patient and hospital factors...
August 3, 2018: Psychiatric Services: a Journal of the American Psychiatric Association
https://www.readbyqxmd.com/read/29731779/early-changes-in-tumor-perfusion-from-t1-weighted-dynamic-contrast-enhanced-mri-following-neural-stem-cell-mediated-therapy-of-recurrent-high-grade-glioma-correlate-with-overall-survival
#5
Prativa Sahoo, Paul Frankel, Julie Ressler, Margarita Gutova, Alexander J Annala, Behnam Badie, Jana Portnow, Karen S Aboody, Massimo D'Apuzzo, Russell C Rockne
Background: The aim of this study was to correlate T1-weighted dynamic contrast-enhanced MRI- (DCE-MRI-) derived perfusion parameters with overall survival of recurrent high-grade glioma patients who received neural stem cell- (NSC-) mediated enzyme/prodrug gene therapy. Methods: A total of 12 patients were included in this retrospective study. All patients were enrolled in a first-in-human study (NCT01172964) of NSC-mediated therapy for recurrent high-grade glioma...
2018: Stem Cells International
https://www.readbyqxmd.com/read/29720725/inhibition-of-gpr158-by-microrna-449a-suppresses-neural-lineage-of-glioma-stem-progenitor-cells-and-correlates-with-higher-glioma-grades
#6
Ningning Li, Ying Zhang, Kastytis Sidlauskas, Matthew Ellis, Ian Evans, Paul Frankel, Joanne Lau, Tedani El-Hassan, Loredana Guglielmi, Jessica Broni, Angela Richard-Loendt, Sebastian Brandner
To identify biomarkers for glioma growth, invasion and progression, we used a candidate gene approach in mouse models with two complementary brain tumour phenotypes, developing either slow-growing, diffusely infiltrating gliomas or highly proliferative, non-invasive primitive neural tumours. In a microRNA screen we first identified microRNA-449a as most significantly differentially expressed between these two tumour types. miR-449a has a target dependent effect, inhibiting cell growth and migration by downregulation of CCND1 and suppressing neural phenotypes by inhibition of G protein coupled-receptor (GPR) 158...
May 3, 2018: Oncogene
https://www.readbyqxmd.com/read/29648813/small-molecule-neuropilin-1-antagonists-combine-antiangiogenic-and-antitumor-activity-with-immune-modulation-through-reduction-of-transforming-growth-factor-beta-tgf%C3%AE-production-in-regulatory-t-cells
#7
Jonathan Powell, Filipa Mota, David Steadman, Christelle Soudy, Jeremy T Miyauchi, Stuart Crosby, Ashley Jarvis, Tifelle Reisinger, Natalie Winfield, Graham Evans, Aled Finniear, Tamas Yelland, Yi-Tai Chou, A W Edith Chan, Andrew O'Leary, Lili Cheng, Dan Liu, Constantina Fotinou, Carla Milagre, John F Martin, Haiyan Jia, Paul Frankel, Snezana Djordjevic, Stella E Tsirka, Ian C Zachary, David L Selwood
We report the design, synthesis, and biological evaluation of some potent small-molecule neuropilin-1 (NRP1) antagonists. NRP1 is implicated in the immune response to tumors, particularly in Treg cell fragility, required for PD1 checkpoint blockade. The design of these compounds was based on a previously identified compound EG00229. The design of these molecules was informed and supported by X-ray crystal structures. Compound 1 (EG01377) was identified as having properties suitable for further investigation...
May 10, 2018: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29596542/assessment-of-tumor-sequencing-as-a-replacement-for-lynch-syndrome-screening-and-current-molecular-tests-for-patients-with-colorectal-cancer
#8
Heather Hampel, Rachel Pearlman, Mallory Beightol, Weiqiang Zhao, Daniel Jones, Wendy L Frankel, Paul J Goodfellow, Ahmet Yilmaz, Kristin Miller, Jason Bacher, Angela Jacobson, Electra Paskett, Peter G Shields, Richard M Goldberg, Albert de la Chapelle, Brian H Shirts, Colin C Pritchard
Importance: Universal tumor screening for Lynch syndrome (LS) in colorectal cancer (CRC) is recommended and involves up to 6 sequential tests. Somatic gene testing is performed on stage IV CRCs for treatment determination. The diagnostic workup for patients with CRC could be simplified and improved using a single up-front tumor next-generation sequencing test if it has higher sensitivity and specificity than the current screening protocol. Objective: To determine whether up-front tumor sequencing (TS) could replace the current multiple sequential test approach for universal tumor screening for LS...
June 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29541413/combined-modality-radiation-therapy-promotes-tolerogenic-myeloid-cell-populations-and-stat3-related-gene-expression-in-head-and-neck-cancer-patients
#9
Sagus Sampath, Haejung Won, Erminia Massarelli, Min Li, Paul Frankel, Nayana Vora, Lalit Vora, Ellie Maghami, Marcin Kortylewski
Immunomodulation contributes to the antitumor efficacy of the fractionated radiation therapy (RT). Here, we describe immune effects of RT with concurrent systemic cisplatin or cetuximab treatment of patients with stage III-IV head and neck squamous cell carcinoma (HNSCC). Using longitudinally collected blood samples, we identified significant changes in cytokines/chemokines and immune cell populations compared to immune-related gene expression profiles in peripheral blood mononuclear cells (PBMCs). The 7-week combinatorial RT resulted in gradual elevation of proinflammatory mediators (IFNγ, IL-6, TNFɑ, CCL2), while levels of IL-12, cytokine essential for antitumor immune responses, were decreased...
February 16, 2018: Oncotarget
https://www.readbyqxmd.com/read/29430837/architecture-and-hydration-of-the-arginine-binding-site-of-neuropilin-1
#10
Filipa Mota, Constantina Fotinou, Rohini R Rana, A W Edith Chan, Tamas Yelland, Mohamed T Arooz, Andrew P O'Leary, Jennie Hutton, Paul Frankel, Ian Zachary, David Selwood, Snezana Djordjevic
Neuropilin-1 (NRP1) is a transmembrane co-receptor involved in binding interactions with variety of ligands and receptors, including receptor tyrosine kinases. Expression of NRP1 in several cancers correlates with cancer stages and poor prognosis. Thus, NRP1 has been considered a therapeutic target and is the focus of multiple drug discovery initiatives. Vascular endothelial growth factor (VEGF) binds to the b1 domain of NRP1 through interactions between the C-terminal arginine of VEGF and residues in the NRP1-binding site including Tyr297, Tyr353, Asp320, Ser346 and Thr349...
April 2018: FEBS Journal
https://www.readbyqxmd.com/read/29301826/p53-reactive-t-cells-are-associated-with-clinical-benefit-in-patients-with-platinum-resistant-epithelial-ovarian-cancer-after-treatment-with-a-p53-vaccine-and-gemcitabine-chemotherapy
#11
Nicola R Hardwick, Paul Frankel, Christopher Ruel, Julie Kilpatrick, Weimin Tsai, Ferdynand Kos, Teodora Kaltcheva, Lucille Leong, Robert Morgan, Vincent Chung, Raechelle Tinsley, Melissa Eng, Sharon Wilczynski, Joshua D I Ellenhorn, Don J Diamond, Mihaela Cristea
Purpose: To conduct a phase I trial of a Modified Vaccinia Ankara vaccine delivering wild-type human p53 (p53MVA) in combination with gemcitabine chemotherapy in patients with platinum-resistant ovarian cancer. Experimental Design: Patients received gemcitabine on days 1 and 8 and p53MVA vaccine on day 15, during the first 3 cycles of chemotherapy. Toxicity was classified using the NCI Common Toxicity Criteria and clinical response assessed by CT scan. Peripheral blood samples were collected for immunophenotyping and monitoring of anti-p53 immune responses...
March 15, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29299355/pilot-trial-of-crlx101-in-patients-with-advanced-chemotherapy-refractory-gastroesophageal-cancer
#12
Joseph Chao, James Lin, Paul Frankel, Andrew J Clark, Devin T Wiley, Edward Garmey, Marwan Fakih, Dean Lim, Vincent Chung, Eloise Luevanos, Scott Eliasof, Mark E Davis, Yun Yen
Background: CRLX101 is an investigational nanoparticle-drug conjugate with a camptothecin payload. Preclinical evidence indicated preferential uptake in tumors, and tumor xenograft models demonstrate superiority of CRLX101 over irinotecan. A pilot trial was conducted at recommended phase 2 dosing (RP2D) using the bimonthly schedule to assess preferential uptake of CRLX101 in tumor vs . adjacent normal tissue in endoscopically accessible tumors in chemotherapy-refractory gastroesophageal cancer...
December 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29108355/a-phase-i-clinical-trial-of-binimetinib-in-combination-with-folfox-in-patients-with-advanced-metastatic-colorectal-cancer-who-failed-prior-standard-therapy
#13
May Cho, Jun Gong, Paul Frankel, Timothy W Synold, Dean Lim, Vincent Chung, Joseph Chao, Daneng Li, Yuan Chen, Stephen Sentovich, Kurt Melstrom, Gagandeep Singh, Eloise Luevanos, Marwan Fakih
Background: This was a first in-human, open-label, dose-escalation phase I study conducted to evaluate the maximum tolerated dose (MTD), safety, and efficacy of the combination of oral binimetinib and FOLFOX. Materials and Methods: Patients with metastatic colorectal cancer (mCRC) who progressed on prior standard therapies received twice daily binimetinib continuously or intermittently with FOLFOX. Dose-limiting toxicities (DLTs) were assessed in the first 2 cycles of study treatment...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/28977992/correction-genomic-mutation-driven-metastatic-breast-cancer-therapy-a-single-center-experience
#14
Yuan Yuan, Susan E Yost, John Yim, Yate-Ching Yuan, Nicola M Solomon, Isa Mambetsariev, Sumanta Pal, Paul Frankel, Ravi Salgia, Susan L Neuhausen, Joanne Mortimer
[This corrects the article DOI: 10.18632/oncotarget.14476.].
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28910150/phase-i-ii-trial-of-anticarcinoembryonic-antigen-radioimmunotherapy-gemcitabine-and-hepatic-arterial-infusion-of-fluorodeoxyuridine-postresection-of-liver-metastasis-for-colorectal-carcinoma
#15
Benjamin Cahan, Lucille Leong, Lawrence Wagman, David Yamauchi, Stephen Shibata, Sharon Wilzcynski, Lawrence E Williams, Paul Yazaki, David Colcher, Paul Frankel, Anna Wu, Andrew Raubitschek, John Shively, Jeffrey Y C Wong
OBJECTIVES: Report the feasibility, toxicities, and long-term results of a Phase I/II trial of 90 Y-labeled anticarcinoembryonic antigen (anti-CEA) (cT84.66) radioimmunotherapy (RIT), gemcitabine, and hepatic arterial infusion (HAI) of fluorodeoxyuridine (FUdR) after maximal hepatic resection of metastatic colorectal cancer to the liver. METHODS: Patients with metastatic colorectal cancer to the liver postresection or ablation to minimum disease were eligible. Each cohort received HAI of FUdR for 14 days on a dose escalation schedule...
September 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28746914/a-phase-i-clinical-trial-of-binimetinib-in-combination-with-folfox-in-patients-with-advanced-metastatic-colorectal-cancer-who-failed-prior-standard-therapy
#16
May Cho, Jun Gong, Paul Frankel, Timothy W Synold, Dean Lim, Vincent Chung, Joseph Chao, Daneng Li, Yuan Chen, Stephen Sentovich, Kurt Melstrom, Gagandeep Singh, Eloise Luevanos, Marwan Fakih
BACKGROUND: This was a first in-human, open-label, dose-escalation phase I study conducted to evaluate the maximum tolerated dose (MTD), safety, and efficacy of the combination of oral binimetinib and FOLFOX. MATERIALS AND METHODS: Patients with metastatic colorectal cancer (mCRC) who progressed on prior standard therapies received twice daily binimetinib continuously or intermittently with FOLFOX. Dose-limiting toxicities (DLTs) were assessed in the first 2 cycles of study treatment...
July 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28709704/epigenetic-silencing-of-mlh1-in-endometrial-cancers-is-associated-with-larger-tumor-volume-increased-rate-of-lymph-node-positivity-and-reduced-recurrence-free-survival
#17
Casey M Cosgrove, David E Cohn, Heather Hampel, Wendy L Frankel, Dan Jones, Joseph P McElroy, Adrian A Suarez, Weiqiang Zhao, Wei Chen, Ritu Salani, Larry J Copeland, David M O'Malley, Jeffrey M Fowler, Ahmet Yilmaz, Alexis S Chassen, Rachel Pearlman, Paul J Goodfellow, Floor J Backes
OBJECTIVES: To determine the relationship between mismatch repair (MMR) classification and clinicopathologic features including tumor volume, and explore outcomes by MMR class in a contemporary cohort. METHODS: Single institution cohort evaluating MMR classification for endometrial cancers (EC). MMR immunohistochemistry (IHC)±microsatellite instability (MSI) testing and reflex MLH1 methylation testing was performed. Tumors with MMR abnormalities by IHC or MSI and MLH1 methylation were classified as epigenetic MMR deficiency while those without MLH1 methylation were classified as probable MMR mutations...
September 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28637802/tumor-uptake-of-64-cu-dota-trastuzumab-in-patients-with-metastatic-breast-cancer
#18
Joanne E Mortimer, James R Bading, Jinha M Park, Paul H Frankel, Mary I Carroll, Tri T Tran, Erasmus K Poku, Russell C Rockne, Andrew A Raubitschek, John E Shively, David M Colcher
The goal of this study was to characterize the relationship between tumor uptake of 64 Cu-DOTA-trastuzumab as measured by PET/CT and standard, immunohistochemistry (IHC)-based, histopathologic classification of human epidermal growth factor receptor 2 (HER2) status in women with metastatic breast cancer (MBC). Methods: Women with biopsy-confirmed MBC and not given trastuzumab for 2 mo or more underwent complete staging, including 18 F-FDG PET/CT. Patients were classified as HER2-positive (HER2+) or -negative (HER2-) based on fluorescence in situ hybridization (FISH)-supplemented immunohistochemistry of biopsied tumor tissue...
January 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28526750/pdgf-controls-contact-inhibition-of-locomotion-by-regulating-n-cadherin-during-neural-crest-migration
#19
Isabel Bahm, Elias H Barriga, Antonina Frolov, Eric Theveneau, Paul Frankel, Roberto Mayor
A fundamental property of neural crest (NC) migration is contact inhibition of locomotion (CIL), a process by which cells change their direction of migration upon cell contact. CIL has been proven to be essential for NC migration in amphibians and zebrafish by controlling cell polarity in a cell contact-dependent manner. Cell contact during CIL requires the participation of the cell adhesion molecule N-cadherin, which starts to be expressed by NC cells as a consequence of the switch between E- and N-cadherins during epithelial-to-mesenchymal transition (EMT)...
July 1, 2017: Development
https://www.readbyqxmd.com/read/28356425/efficacy-of-the-parp-inhibitor-veliparib-with-carboplatin-or-as-a-single-agent-in-patients-with-germline-brca1-or-brca2-associated-metastatic-breast-cancer-california-cancer-consortium-trial-nct01149083
#20
George Somlo, Paul H Frankel, Banu K Arun, Cynthia X Ma, Agustin A Garcia, Tessa Cigler, Leah V Cream, Harold A Harvey, Joseph A Sparano, Rita Nanda, Helen K Chew, Timothy J Moynihan, Linda T Vahdat, Matthew P Goetz, Jan H Beumer, Arti Hurria, Joanne Mortimer, Richard Piekarz, Sharon Sand, Josef Herzog, Lily R Van Tongeren, Katherine V Ferry-Galow, Alice P Chen, Christopher Ruel, Edward M Newman, David R Gandara, Jeffrey N Weitzel
Purpose: We aimed to establish the MTD of the poly (ADP-ribose) (PAR) polymerase inhibitor, veliparib, in combination with carboplatin in germline BRCA1 - and BRCA2- (BRCA) -associated metastatic breast cancer (MBC), to assess the efficacy of single-agent veliparib, and of the combination treatment after progression, and to correlate PAR levels with clinical outcome. Experimental Design: Phase I patients received carboplatin (AUC of 5-6, every 21 days), with escalating doses (50-20 mg) of oral twice-daily (BID) veliparib...
August 1, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
996
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"